Vivos Inc. announced significant achievements for its IsoPet Animal Cancer Division in 2024, highlighting its growth and innovation in veterinary cancer care. In May 2024, IsoPet was established as a standalone division within Vivos Inc., underscoring the company's commitment to advancing animal cancer treatments. This move was supported by a dedicated team focused on expanding IsoPet's reach.
The company reported an expansion of its network of certified veterinary clinics across the U.S. and increased engagement through nationwide marketing and social media campaigns. Vivos Inc. aims to further expand its network of small animal, equine, and exotic clinics in 2025 and 2026, while increasing the number of patients benefiting from IsoPet treatments.
The global veterinary oncology market was valued at $1.18 billion in 2023 and is projected to grow at an 11.3% Compound Annual Growth Rate from 2024 to 2030. With approximately 6 million dogs and 6 million cats diagnosed with cancer annually in the U.S., IsoPet is positioned to address a portion of this growing demand with its minimally invasive treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.